Is Oxford Pharmascience Group Plc a Sell? The Stock Declines Again

 Is Oxford Pharmascience Group Plc a Sell? The Stock Declines Again

The stock of Oxford Pharmascience Group Plc (LON:OXP) is a huge mover today! The stock decreased 2.44% or GBX 0.05 on November 8, hitting GBX 2. About 2.20 million shares traded hands. Oxford Pharmascience Group Plc (LON:OXP) has declined 51.76% since April 8, 2016 and is downtrending. It has underperformed by 53.72% the S&P500.
The move comes after 9 months negative chart setup for the GBX 23.26 million company. It was reported on Nov, 8 by We have GBX 1.74 PT which if reached, will make LON:OXP worth GBX 3.02M less.

Oxford Pharmascience Group Plc (LON:OXP) Ratings Coverage

Out of 2 analysts covering Oxford Pharmascience Group PLC (LON:OXP), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Oxford Pharmascience Group PLC has been the topic of 7 analyst reports since July 31, 2015 according to StockzIntelligence Inc. N+1 Singer maintained the shares of OXP in a report on Tuesday, September 22 with “Corporate” rating. The company was maintained on Wednesday, August 12 by N+1 Singer. On Thursday, July 21 the stock rating was downgraded by Beaufort Securities to “Hold”. N+1 Singer maintained the stock with “Corporate” rating in Friday, July 31 report. The rating was maintained by N+1 Singer with “Corporate” on Monday, January 25. The rating was maintained by N+1 Singer on Thursday, November 5 with “Corporate”. The firm earned “Speculative Buy” rating on Monday, March 7 by Beaufort Securities.

More news for Oxford Pharmascience Group Plc (LON:OXP) were recently published by:, which released: “Oxford Pharmascience Group Plc (OXP.L)” on March 17, 2014. Fool.Co.Uk‘s article titled: “Should You Follow Neil Woodford And Buy GlaxoSmithKline plc, AstraZeneca plc …” and published on March 03, 2015 is yet another important article.

Oxford Pharmascience Group plc is a United Kingdom specialty pharmaceutical company. The company has a market cap of 23.26 million GBP. The Firm is engaged in re-developing medicines. It currently has negative earnings. The Firm engages in research and development activities based around its core technology platforms and focuses on commercializing the related products to pharmaceutical organizations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment